Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
MigraineChronic Migraine
Interventions
BIOLOGICAL

Eptinezumab

The study treatment consists of a single infusion of eptinezumab (100mg/mL).

OTHER

Standard of Care

SoC may include a combination of Toradol, Metoclopramide, and/or Benadryl. Ketamine and/or Midazolam may also be used, according to a stepwise approach, at the discretion of the treating physician. The timing and dose of all medication(s) administered in the ED will be recorded.

Trial Locations (2)

V3L 3W7

Royal Columbian Hospital, New Westminster

V3V 1Z2

Surrey Memorial Hospital, Surrey

All Listed Sponsors
collaborator

H. Lundbeck A/S

INDUSTRY

collaborator

Centre for Neurology Studies, Surrey Neuroplasticity Clinic Inc.

UNKNOWN

collaborator

Royal Columbian Hospital Foundation

OTHER

collaborator

Surrey Memorial Hospital

UNKNOWN

lead

Dr George Medvedev

INDUSTRY